April 26, 2024 11:12 AM Eastern Daylight Time FRAMINGHAM, Mass.–(BUSINESS WIRE)–Variantyx, a leader in molecular diagnostics, announced today that it has secured an additional $36 million in funding from its portfolio of investors which includes…
According to filings with the U.S. Securities and Exchange Commission, Alzheon is raising up to $49,995,798.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Martin Tolar played…
Framingham, MA – According to filings with the U.S. Securities and Exchange Commission, Arch Therapeutics is raising $7,520,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Terrence Norchi…
Framingham, MA – According to filings with the U.S. Securities and Exchange Commission, Bluespec is raising $2,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Charles Hauck played a key…
Framingham, MA – According to filings with the U.S. Securities and Exchange Commission, Re:Build Manufacturing is raising $27,615,000.00 in new funding. Sources indicate as part of senior management Chief Financial Officer, Gordon O’Brien played a…
Framingham, Massachusetts — According to state and local economic development sources CRISPR Therapeutics plans to build out new space in Framingham. The company plans to occupy the new space in Framingham, on or about March 1,…
Framingham, MA – According to filings with the U.S. Securities and Exchange Commission, Solace Therapeutics is raising $17,550,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, William Gruber…
Framingham, MA – According to filings with the U.S. Securities and Exchange Commission, Alzheon is raising $6,163,716.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Martin Tolar played a key…